Current Neuropharmacology

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back Subscribe
General Review Article

Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease

Author(s): Busra Ozturk, Huriye Demir, Mine Silindir Gunay, Yagmur Akdag, Selma Sahin and Tugba Gulsun*

Volume 23, Issue 14, 2025

Published on: 15 April, 2025

Page: [1985 - 2003] Pages: 19

DOI: 10.2174/011570159X370790250317045223

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Alzheimer's disease is a neurodegenerative disease that impairs cognitive function. The incidence of Alzheimer's disease increases with the increase in the elderly population. Although the clear pathogenesis of Alzheimer's disease is not yet known, the formation of amyloid plaques and tau fibrils, diminished acetylcholine levels, and increased inflammation can be observed in patients. Alzheimer's disease, whose pathogenesis is not fully demonstrated, cannot be treated radically. Since it has been observed that only pharmacological treatment alone isn’t sufficient, alternative approaches have become essential. Among these approaches, nanocarriers greatly facilitate the transport of drugs since the blood-brain barrier is an important obstacle to the penetration of drugs into the brain. Photosensitizers trigger activation after exposure to near-infrared radiation light of a suitable wavelength or laser light, resulting in the selective destruction of Aβ plaques. Photodynamic therapy and photothermal therapy have been investigated for their potential to inhibit Aβ plaques through photosensitizers. By ThT fluorescence measurements, TAS-loaded Ce6 micelles show inhibiting Aβ monomers from formation Aβ aggregates and degradation of protofibrills to small fragments. By using these photosensitizers, near-infrared radiation fluorescence imaging can be used as a theranostic. In this review, potential treatment options for photodynamic therapy and photothermal therapy for Alzheimer's disease are summarised, and a simultaneous or combined approach is discussed, taking into account potential nanotheranostics.

Keywords: Alzheimer’s disease, drug delivery systems, nanotechnology, nano theranostics, photodynamic therapy, photothermal therapy.

Graphical Abstract

[1]
Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer disease. Nat. Rev. Dis. Primers, 2021, 7(1), 33.
[http://dx.doi.org/10.1038/s41572-021-00269-y] [PMID: 33986301]
[2]
Haaksma, M.L.; Eriksdotter, M.; Rizzuto, D.; Leoutsakos, J.M.S.; Olde Rikkert, M.G.M.; Melis, R.J.F.; Garcia-Ptacek, S. Survival time tool to guide care planning in people with dementia. Neurology, 2020, 94(5), e538-e548.
[http://dx.doi.org/10.1212/WNL.0000000000008745] [PMID: 31843808]
[3]
Nandi, A.; Counts, N.; Chen, S.; Seligman, B.; Tortorice, D.; Vigo, D.; Bloom, D.E. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClin. Med., 2022, 51, 101580.
[http://dx.doi.org/10.1016/j.eclinm.2022.101580] [PMID: 35898316]
[4]
Nichols, E.; Steinmetz, J.D.; Vollset, S.E.; Fukutaki, K.; Chalek, J.; Abd-Allah, F.; Abdoli, A.; Abualhasan, A.; Abu-Gharbieh, E.; Akram, T.T.; Al Hamad, H.; Alahdab, F.; Alanezi, F.M.; Alipour, V.; Almustanyir, S.; Amu, H.; Ansari, I.; Arabloo, J.; Ashraf, T.; Astell-Burt, T.; Ayano, G.; Ayuso-Mateos, J.L.; Baig, A.A.; Barnett, A.; Barrow, A.; Baune, B.T.; Béjot, Y.; Bezabhe, W.M.M.; Bezabih, Y.M.; Bhagavathula, A.S.; Bhaskar, S.; Bhattacharyya, K.; Bijani, A.; Biswas, A.; Bolla, S.R.; Boloor, A.; Brayne, C.; Brenner, H.; Burkart, K.; Burns, R.A.; Cámera, L.A.; Cao, C.; Carvalho, F.; Castro-de-Araujo, L.F.S.; Catalá-López, F.; Cerin, E.; Chavan, P.P.; Cherbuin, N.; Chu, D-T.; Costa, V.M.; Couto, R.A.S.; Dadras, O.; Dai, X.; Dandona, L.; Dandona, R.; De la Cruz-Góngora, V.; Dhamnetiya, D.; Dias da Silva, D.; Diaz, D.; Douiri, A.; Edvardsson, D.; Ekholuenetale, M.; El Sayed, I.; El-Jaafary, S.I.; Eskandari, K.; Eskandarieh, S.; Esmaeilnejad, S.; Fares, J.; Faro, A.; Farooque, U.; Feigin, V.L.; Feng, X.; Fereshtehnejad, S-M.; Fernandes, E.; Ferrara, P.; Filip, I.; Fillit, H.; Fischer, F.; Gaidhane, S.; Galluzzo, L.; Ghashghaee, A.; Ghith, N.; Gialluisi, A.; Gilani, S.A.; Glavan, I-R.; Gnedovskaya, E.V.; Golechha, M.; Gupta, R.; Gupta, V.B.; Gupta, V.K.; Haider, M.R.; Hall, B.J.; Hamidi, S.; Hanif, A.; Hankey, G.J.; Haque, S.; Hartono, R.K.; Hasaballah, A.I.; Hasan, M.T.; Hassan, A.; Hay, S.I.; Hayat, K.; Hegazy, M.I.; Heidari, G.; Heidari-Soureshjani, R.; Herteliu, C.; Househ, M.; Hussain, R.; Hwang, B-F.; Iacoviello, L.; Iavicoli, I.; Ilesanmi, O.S.; Ilic, I.M.; Ilic, M.D.; Irvani, S.S.N.; Iso, H.; Iwagami, M.; Jabbarinejad, R.; Jacob, L.; Jain, V.; Jayapal, S.K.; Jayawardena, R.; Jha, R.P.; Jonas, J.B.; Joseph, N.; Kalani, R.; Kandel, A.; Kandel, H.; Karch, A.; Kasa, A.S.; Kassie, G.M.; Keshavarz, P.; Khan, M.A.B.; Khatib, M.N.; Khoja, T.A.M.; Khubchandani, J.; Kim, M.S.; Kim, Y.J.; Kisa, A.; Kisa, S.; Kivimäki, M.; Koroshetz, W.J.; Koyanagi, A.; Kumar, G.A.; Kumar, M.; Lak, H.M.; Leonardi, M.; Li, B.; Lim, S.S.; Liu, X.; Liu, Y.; Logroscino, G.; Lorkowski, S.; Lucchetti, G.; Lutzky Saute, R.; Magnani, F.G.; Malik, A.A.; Massano, J.; Mehndiratta, M.M.; Menezes, R.G.; Meretoja, A.; Mohajer, B.; Mohamed Ibrahim, N.; Mohammad, Y.; Mohammed, A.; Mokdad, A.H.; Mondello, S.; Moni, M.A.A.; Moniruzzaman, M.; Mossie, T.B.; Nagel, G.; Naveed, M.; Nayak, V.C.; Neupane Kandel, S.; Nguyen, T.H.; Oancea, B.; Otstavnov, N.; Otstavnov, S.S.; Owolabi, M.O.; Panda-Jonas, S.; Pashazadeh Kan, F.; Pasovic, M.; Patel, U.K.; Pathak, M.; Peres, M.F.P.; Perianayagam, A.; Peterson, C.B.; Phillips, M.R.; Pinheiro, M.; Piradov, M.A.; Pond, C.D.; Potashman, M.H.; Pottoo, F.H.; Prada, S.I.; Radfar, A.; Raggi, A.; Rahim, F.; Rahman, M.; Ram, P.; Ranasinghe, P.; Rawaf, D.L.; Rawaf, S.; Rezaei, N.; Rezapour, A.; Robinson, S.R.; Romoli, M.; Roshandel, G.; Sahathevan, R.; Sahebkar, A.; Sahraian, M.A.; Sathian, B.; Sattin, D.; Sawhney, M.; Saylan, M.; Schiavolin, S.; Seylani, A.; Sha, F.; Shaikh, M.A.; Shaji, K.S.; Shannawaz, M.; Shetty, J.K.; Shigematsu, M.; Shin, J.I.; Shiri, R.; Silva, D.A.S.; Silva, J.P.; Silva, R.; Singh, J.A.; Skryabin, V.Y.; Skryabina, A.A.; Smith, A.E.; Soshnikov, S.; Spurlock, E.E.; Stein, D.J.; Sun, J.; Tabarés-Seisdedos, R.; Thakur, B.; Timalsina, B.; Tovani-Palone, M.R.; Tran, B.X.; Tsegaye, G.W.; Valadan Tahbaz, S.; Valdez, P.R.; Venketasubramanian, N.; Vlassov, V.; Vu, G.T.; Vu, L.G.; Wang, Y-P.; Wimo, A.; Winkler, A.S.; Yadav, L.; Yahyazadeh Jabbari, S.H.; Yamagishi, K.; Yang, L.; Yano, Y.; Yonemoto, N.; Yu, C.; Yunusa, I.; Zadey, S.; Zastrozhin, M.S.; Zastrozhina, A.; Zhang, Z-J.; Murray, C.J.L.; Vos, T. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the global burden of disease study 2019. Lancet Public Health, 2022, 7(2), e105-e125.
[http://dx.doi.org/10.1016/S2468-2667(21)00249-8] [PMID: 34998485]
[5]
Nichols, E.; Szoeke, C.E.I.; Vollset, S.E.; Abbasi, N.; Abd-Allah, F.; Abdela, J.; Aichour, M.T.E.; Akinyemi, R.O.; Alahdab, F.; Asgedom, S.W.; Awasthi, A.; Barker-Collo, S.L.; Baune, B.T.; Béjot, Y.; Belachew, A.B.; Bennett, D.A.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Brayne, C.; Carpenter, D.O.; Carvalho, F.; Catalá-López, F.; Cerin, E.; Choi, J-Y.J.; Dang, A.K.; Degefa, M.G.; Djalalinia, S.; Dubey, M.; Duken, E.E.; Edvardsson, D.; Endres, M.; Eskandarieh, S.; Faro, A.; Farzadfar, F.; Fereshtehnejad, S-M.; Fernandes, E.; Filip, I.; Fischer, F.; Gebre, A.K.; Geremew, D.; Ghasemi-Kasman, M.; Gnedovskaya, E.V.; Gupta, R.; Hachinski, V.; Hagos, T.B.; Hamidi, S.; Hankey, G.J.; Haro, J.M.; Hay, S.I.; Irvani, S.S.N.; Jha, R.P.; Jonas, J.B.; Kalani, R.; Karch, A.; Kasaeian, A.; Khader, Y.S.; Khalil, I.A.; Khan, E.A.; Khanna, T.; Khoja, T.A.M.; Khubchandani, J.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Koyanagi, A.; Krohn, K.J.; Logroscino, G.; Lorkowski, S.; Majdan, M.; Malekzadeh, R.; März, W.; Massano, J.; Mengistu, G.; Meretoja, A.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mokdad, A.H.; Mondello, S.; Moradi, G.; Nagel, G.; Naghavi, M.; Naik, G.; Nguyen, L.H.; Nguyen, T.H.; Nirayo, Y.L.; Nixon, M.R.; Ofori-Asenso, R.; Ogbo, F.A.; Olagunju, A.T.; Owolabi, M.O.; Panda-Jonas, S.; Passos, V.M.A.; Pereira, D.M.; Pinilla-Monsalve, G.D.; Piradov, M.A.; Pond, C.D.; Poustchi, H.; Qorbani, M.; Radfar, A.; Reiner, R.C., Jr; Robinson, S.R.; Roshandel, G.; Rostami, A.; Russ, T.C.; Sachdev, P.S.; Safari, H.; Safiri, S.; Sahathevan, R.; Salimi, Y.; Satpathy, M.; Sawhney, M.; Saylan, M.; Sepanlou, S.G.; Shafieesabet, A.; Shaikh, M.A.; Sahraian, M.A.; Shigematsu, M.; Shiri, R.; Shiue, I.; Silva, J.P.; Smith, M.; Sobhani, S.; Stein, D.J.; Tabarés-Seisdedos, R.; Tovani-Palone, M.R.; Tran, B.X.; Tran, T.T.; Tsegay, A.T.; Ullah, I.; Venketasubramanian, N.; Vlassov, V.; Wang, Y-P.; Weiss, J.; Westerman, R.; Wijeratne, T.; Wyper, G.M.A.; Yano, Y.; Yimer, E.M.; Yonemoto, N.; Yousefifard, M.; Zaidi, Z.; Zare, Z.; Vos, T.; Feigin, V.L.; Murray, C.J.L. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet Neurol., 2019, 18(1), 88-106.
[http://dx.doi.org/10.1016/S1474-4422(18)30403-4] [PMID: 30497964]
[6]
Devkota, S.; Williams, T.D.; Wolfe, M.S. Familial Alzheimer’s disease mutations in amyloid protein precursor alter proteolysis by γ-secretase to increase amyloid β-peptides of ≥45 residues. J. Biol. Chem., 2021, 296, 100281.
[http://dx.doi.org/10.1016/j.jbc.2021.100281] [PMID: 33450230]
[7]
Sharma, P.; Srivastava, P.; Seth, A.; Tripathi, P.N.; Banerjee, A.G.; Shrivastava, S.K. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog. Neurobiol., 2019, 174, 53-89.
[http://dx.doi.org/10.1016/j.pneurobio.2018.12.006] [PMID: 30599179]
[8]
Kumar, A.; Singh, A.; Ekavali. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep., 2015, 67(2), 195-203.
[http://dx.doi.org/10.1016/j.pharep.2014.09.004] [PMID: 25712639]
[9]
Oda, T.; Wals, P.; Osterburg, H.H.; Johnson, S.A.; Pasinetti, G.M.; Morgan, T.E.; Rozovsky, I.; Stine, W.B.; Snyder, S.W.; Holzman, T.F.; Krafft, G.A.; Finch, C.E. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol., 1995, 136(1), 22-31.
[http://dx.doi.org/10.1006/exnr.1995.1080] [PMID: 7589331]
[10]
Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
[http://dx.doi.org/10.1126/science.1072994] [PMID: 12130773]
[11]
Reitz, C. Novel susceptibility loci for Alzheimer’s disease. Future Neurol., 2015, 10(6), 547-558.
[http://dx.doi.org/10.2217/fnl.15.42] [PMID: 27057151]
[12]
Ma, C.; Hong, F.; Yang, S. Amyloidosis in Alzheimer’s disease: Pathogeny, etiology, and related therapeutic directions. Molecules, 2022, 27(4), 1210.
[http://dx.doi.org/10.3390/molecules27041210] [PMID: 35209007]
[13]
Cárdenas, A.M.; Ardiles, A.O.; Barraza, N.; Baéz-Matus, X.; Caviedes, P. Role of tau protein in neuronal damage in Alzheimer’s disease and Down syndrome. Arch. Med. Res., 2012, 43(8), 645-654.
[http://dx.doi.org/10.1016/j.arcmed.2012.10.012] [PMID: 23142525]
[14]
Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA, 1986, 83(11), 4040-4043.
[http://dx.doi.org/10.1073/pnas.83.11.4040] [PMID: 2424015]
[15]
Noble, W.; Pooler, A.M.; Hanger, D.P. Advances in tau-based drug discovery. Expert Opin. Drug Discov., 2011, 6(8), 797-810.
[http://dx.doi.org/10.1517/17460441.2011.586690] [PMID: 22003359]
[16]
Wu, X.L.; Piña-Crespo, J.; Zhang, Y.W.; Chen, X.C.; Xu, H.X. Tau-mediated neurodegeneration and potential ımplications in diagnosis and treatment of Alzheimer’s disease. Chin. Med. J., 2017, 130(24), 2978-2990.
[http://dx.doi.org/10.4103/0366-6999.220313] [PMID: 29237931]
[17]
Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules, 2019, 24(8), 1583.
[http://dx.doi.org/10.3390/molecules24081583] [PMID: 31013638]
[18]
Praticò, D. Oxidative stress hypothesis in Alzheimer’s disease: A reappraisal. Trends Pharmacol. Sci., 2008, 29(12), 609-615.
[http://dx.doi.org/10.1016/j.tips.2008.09.001] [PMID: 18838179]
[19]
Persson, T.; Popescu, B.O.; Cedazo-Minguez, A. Oxidative stress in Alzheimer’s disease: Why did antioxidant therapy fail? Oxid. Med. Cell. Longev., 2014, 2014, 1-11.
[http://dx.doi.org/10.1155/2014/427318] [PMID: 24669288]
[20]
DeKosky, S.T.; Scheff, S.W.; Styren, S.D. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration, 1996, 5(4), 417-421.
[http://dx.doi.org/10.1006/neur.1996.0056] [PMID: 9117556]
[21]
Mash, D.C.; Flynn, D.D.; Potter, L.T. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science, 1985, 228(4703), 1115-1117.
[http://dx.doi.org/10.1126/science.3992249] [PMID: 3992249]
[22]
Teaktong, T.; Graham, A.J.; Court, J.A.; Perry, R.H.; Jaros, E.; Johnson, M.; Hall, R.; Perry, E.K. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer’s disease and dementia with Lewy bodies: Differential neuronal and astroglial pathology. J. Neurol. Sci., 2004, 225(1-2), 39-49.
[http://dx.doi.org/10.1016/j.jns.2004.06.015] [PMID: 15465084]
[23]
Kocahan, S.; Doğan, Z. Mechanisms of Alzheimer’s disease pathogenesis and prevention: The brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin. Psychopharmacol. Neurosci., 2017, 15(1), 1-8.
[http://dx.doi.org/10.9758/cpn.2017.15.1.1] [PMID: 28138104]
[24]
Wang, R.; Reddy, P.H. Role of glutamate and NMDA receptors in Alzheimer’s disease. J. Alzheimers Dis., 2017, 57(4), 1041-1048.
[http://dx.doi.org/10.3233/JAD-160763] [PMID: 27662322]
[25]
Ghersi, M.S.; Gabach, L.A.; Buteler, F.; Vilcaes, A.A.; Schiöth, H.B.; Perez, M.F.; de Barioglio, S.R. Ghrelin increases memory consolidation through hippocampal mechanisms dependent on glutamate release and NR2B-subunits of the NMDA receptor. Psychopharmacology, 2015, 232(10), 1843-1857.
[http://dx.doi.org/10.1007/s00213-014-3817-6] [PMID: 25466701]
[26]
Hynd, M.; Scott, H.L.; Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem. Int., 2004, 45(5), 583-595.
[http://dx.doi.org/10.1016/j.neuint.2004.03.007] [PMID: 15234100]
[27]
Alhazmi, H.A.; Albratty, M. An update on the novel and approved drugs for Alzheimer disease. Saudi Pharm. J., 2022, 30(12), 1755-1764.
[http://dx.doi.org/10.1016/j.jsps.2022.10.004] [PMID: 36601504]
[28]
Jann, M.W. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy, 2000, 20(1), 1-12.
[http://dx.doi.org/10.1592/phco.20.1.1.34664] [PMID: 10641971]
[29]
Winblad, B.; Machado, J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin. Drug Deliv., 2008, 5(12), 1377-1386.
[http://dx.doi.org/10.1517/17425240802542690] [PMID: 19040398]
[30]
Varadharajan, A.; Davis, AD; Ghosh, A.; Jagtap, T.; Xavier, A.; Menon, A.J. Guidelines for pharmacotherapy in Alzheimer’s disease - A primer on FDA-approved drugs. J. Neurosci. Rural Pract., 2023, 14(4), 566-573.
[http://dx.doi.org/10.25259/JNRP_356_2023]
[31]
Scott, L.J.; Goa, K.L. Galantamine: A review of its use in Alzheimer's disease. Drugs, 2000, 60(5), 1095-1122.
[http://dx.doi.org/10.2165/00003495-200060050-00008] [PMID: 11129124]
[32]
Yiannopoulou, K.G.; Papageorgiou, S.G. Current and future treatments for Alzheimer’s disease. Ther. Adv. Neurol. Disord., 2013, 6(1), 19-33.
[http://dx.doi.org/10.1177/1756285612461679] [PMID: 23277790]
[33]
Johnson, J.; Kotermanski, S. Mechanism of action of memantine. Curr. Opin. Pharmacol., 2006, 6(1), 61-67.
[http://dx.doi.org/10.1016/j.coph.2005.09.007] [PMID: 16368266]
[34]
FDA grants accelerated approval for Alzheimer’s drug: FDA. 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
[35]
Dunstan, R; Bussiere, T; Engber, T; Weinreb, P; Maier, M; Grimm, J. P4-006: The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tc2576 with BIIB037 Alzheimer's & Dementia, 2011, 7(4S_Part_20), S700.
[36]
Haddad, H.W.; Malone, G.W.; Comardelle, N.J.; Degueure, A.E.; Poliwoda, S.; Kaye, R.J.; Murnane, K.S.; Kaye, A.M.; Kaye, A.D. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: A comprehensive review. Health Psychol. Res., 2022, 10(2), 37023.
[http://dx.doi.org/10.52965/001c.37023] [PMID: 35910244]
[37]
Arndt, J.W.; Qian, F.; Smith, B.A.; Quan, C.; Kilambi, K.P.; Bush, M.W.; Walz, T.; Pepinsky, R.B.; Bussière, T.; Hamann, S.; Cameron, T.O.; Weinreb, P.H. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep., 2018, 8(1), 6412.
[http://dx.doi.org/10.1038/s41598-018-24501-0] [PMID: 29686315]
[39]
FDA converts novel alzheimer’s disease treatment to traditional approval. 2024. Available from: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-diseasetreatment-traditional-approval
[40]
Canady, V.A. FDA approves new treatment for Alzheimer’s disease. Ment. Health Wkly., 2023, 33(3), 6-7.
[http://dx.doi.org/10.1002/mhw.33505]
[41]
Huang, L.K.; Kuan, Y.C.; Lin, H.W.; Hu, C.J. Clinical trials of new drugs for Alzheimer disease: A 2020–2023 update. J. Biomed. Sci., 2023, 30(1), 83.
[http://dx.doi.org/10.1186/s12929-023-00976-6] [PMID: 37784171]
[42]
Tucker, S.; Möller, C.; Tegerstedt, K.; Lord, A.; Laudon, H.; Sjödahl, J.; Söderberg, L.; Spens, E.; Sahlin, C.; Waara, E.R.; Satlin, A.; Gellerfors, P.; Osswald, G.; Lannfelt, L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimers Dis., 2014, 43(2), 575-588.
[http://dx.doi.org/10.3233/JAD-140741] [PMID: 25096615]
[43]
van Dyck, C.H.; Swanson, C.J.; Aisen, P.; Bateman, R.J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L.D.; Iwatsubo, T. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med., 2023, 388(1), 9-21.
[http://dx.doi.org/10.1056/NEJMoa2212948] [PMID: 36449413]
[44]
Questions and answers on the refusal of the marketing authorisation for Leqembi (lecanemab). 2024. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi
[45]
FDA-approved treatments for Alzheimer’s: Alzheimer's association. 2024. Available from: https://www.alz.org/media/Documents/alzheimers-dementia-fda-approved-treatments-for-alzheimers-ts.pdf
[47]
Medications approved for dementia in Canada: Alzheimer Society of Canada. 2024. Available from: https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments/medications-for-alzheimers
[48]
Abbott, N.J.; Patabendige, A.A.K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
[http://dx.doi.org/10.1016/j.nbd.2009.07.030] [PMID: 19664713]
[49]
López-Ornelas, A.; Jiménez, A.; Pérez-Sánchez, G.; Rodríguez-Pérez, C.E.; Corzo-Cruz, A.; Velasco, I.; Estudillo, E. The impairment of blood-brain barrier in Alzheimer’s disease: Challenges and opportunities with stem cells. Int. J. Mol. Sci., 2022, 23(17), 10136.
[http://dx.doi.org/10.3390/ijms231710136] [PMID: 36077533]
[50]
Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201.
[http://dx.doi.org/10.1016/j.neuron.2008.01.003] [PMID: 18215617]
[51]
Zenaro, E.; Piacentino, G.; Constantin, G. The blood-brain barrier in Alzheimer’s disease. Neurobiol. Dis., 2017, 107, 41-56.
[http://dx.doi.org/10.1016/j.nbd.2016.07.007] [PMID: 27425887]
[52]
Cai, J.; Dao, P.; Chen, H.; Yan, L.; Li, Y.L.; Zhang, W.; Li, L.; Du, Z.; Dong, C-Z.; Meunier, B. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer’s disease. Dyes Pigments, 2020, 173, 107968.
[http://dx.doi.org/10.1016/j.dyepig.2019.107968]
[53]
Rankovic, Z. CNS drug design: Balancing physicochemical properties for optimal brain exposure. J. Med. Chem., 2015, 58(6), 2584-2608.
[http://dx.doi.org/10.1021/jm501535r] [PMID: 25494650]
[54]
Toksoy, M.O.; Tırnaksız, F.F. Solid lipid nanoparticles and their applications as brain-specific drug delivery systems. J. Fac. Pharm. Ankara., 2021, 45(2), 428-442.
[55]
Doğan, S.S.; Çaban, S.; Çapan, Y. Drug targeting strategies to the brain. Hacettepe Uni J Fac Pharm., 2013, (2), 231-250.
[56]
Partridge, B.; Eardley, A.; Morales, B.E.; Campelo, S.N.; Lorenzo, M.F.; Mehta, J.N.; Kani, Y.; Mora, J.K.G.; Campbell, E.O.Y.; Arena, C.B.; Platt, S.; Mintz, A.; Shinn, R.L.; Rylander, C.G.; Debinski, W.; Davalos, R.V.; Rossmeisl, J.H. Advancements in drug delivery methods for the treatment of brain disease. Front. Vet. Sci., 2022, 9, 1039745.
[http://dx.doi.org/10.3389/fvets.2022.1039745] [PMID: 36330152]
[57]
Pardridge, W.M. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2005, 2(1), 3-14.
[http://dx.doi.org/10.1602/neurorx.2.1.3] [PMID: 15717053]
[58]
He, Q.; Liu, J.; Liang, J.; Liu, X.; Li, W.; Liu, Z.; Ding, Z.; Tuo, D. Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells, 2018, 7(4), 24.
[http://dx.doi.org/10.3390/cells7040024] [PMID: 29570659]
[59]
Telano, L.N.; Baker, S. Physiology, cerebral spinal fluid. In: StatPearls; StatPearls Publishing LLC: Treasure Island, FL, 2024.
[60]
Kaya, M.; Ahishali, B. Basic physiology of the blood-brain barrier in health and disease: A brief overview. Tissue Barriers, 2021, 9(1), 1840913.
[http://dx.doi.org/10.1080/21688370.2020.1840913] [PMID: 33190576]
[61]
Damkier, H.H.; Brown, P.D.; Praetorius, J. Cerebrospinal fluid secretion by the choroid plexus. Physiol. Rev., 2013, 93(4), 1847-1892.
[http://dx.doi.org/10.1152/physrev.00004.2013] [PMID: 24137023]
[62]
Chiang, G.C. The blood-cerebrospinal fluid barrier may play a role in alzheimer disease pathogenesis. Radiology, 2022, 304(3), 646-647.
[http://dx.doi.org/10.1148/radiol.220740] [PMID: 35579527]
[63]
Sakka, L.; Coll, G.; Chazal, J. Anatomy and physiology of cerebrospinal fluid. Eur. Ann. Otorhinolaryngol. Head Neck Dis., 2011, 128(6), 309-316.
[http://dx.doi.org/10.1016/j.anorl.2011.03.002] [PMID: 22100360]
[64]
Dubois, B.; Feldman, H.H.; Jacova, C.; Hampel, H.; Molinuevo, J.L.; Blennow, K.; DeKosky, S.T.; Gauthier, S.; Selkoe, D.; Bateman, R.; Cappa, S.; Crutch, S.; Engelborghs, S.; Frisoni, G.B.; Fox, N.C.; Galasko, D.; Habert, M.O.; Jicha, G.A.; Nordberg, A.; Pasquier, F.; Rabinovici, G.; Robert, P.; Rowe, C.; Salloway, S.; Sarazin, M.; Epelbaum, S.; de Souza, L.C.; Vellas, B.; Visser, P.J.; Schneider, L.; Stern, Y.; Scheltens, P.; Cummings, J.L. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol., 2014, 13(6), 614-629.
[http://dx.doi.org/10.1016/S1474-4422(14)70090-0] [PMID: 24849862]
[65]
Kreuter, J. Nanoparticles—a historical perspective. Int. J. Pharm., 2007, 331(1), 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2006.10.021] [PMID: 17110063]
[66]
Sayıner, Ö.; Çomoğlu, T. Nanotaşıyıcı sistemlerde hedeflendirme targetıng wıth nanocarrıer systems. J. Fac. Pharm. Ankara., 2016, 40(3), 62-79.
[67]
Henry, M.S.; Passmore, A.P.; Todd, S.; McGuinness, B.; Craig, D.; Johnston, J.A. The development of effective biomarkers for Alzheimer’s disease: A review. Int. J. Geriatr. Psychiatry, 2013, 28(4), 331-340.
[http://dx.doi.org/10.1002/gps.3829] [PMID: 22674539]
[68]
van Oostveen, W.M.; de Lange, E.C.M. Imaging techniques in Alzheimer’s disease: A review of applications in early diagnosis and longitudinal monitoring. Int. J. Mol. Sci., 2021, 22(4), 2110.
[http://dx.doi.org/10.3390/ijms22042110] [PMID: 33672696]
[69]
Valotassiou, V.; Malamitsi, J.; Papatriantafyllou, J.; Dardiotis, E.; Tsougos, I.; Psimadas, D.; Alexiou, S.; Hadjigeorgiou, G.; Georgoulias, P. SPECT and PET imaging in Alzheimer’s disease. Ann. Nucl. Med., 2018, 32(9), 583-593.
[http://dx.doi.org/10.1007/s12149-018-1292-6] [PMID: 30128693]
[70]
Becker, R.E.; Greig, N.H.; Giacobini, E. Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J. Alzheimers Dis., 2008, 15(2), 303-325.
[http://dx.doi.org/10.3233/JAD-2008-15213] [PMID: 18953116]
[71]
Parveen, S.; Sahoo, S.K. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin. Pharmacokinet., 2006, 45(10), 965-988.
[http://dx.doi.org/10.2165/00003088-200645100-00002] [PMID: 16984211]
[72]
Nguyen, T.T.; Nguyen, T.T.D.; Nguyen, T.K.O.; Vo, T.K.; Vo, V.G. Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed. Pharmacother., 2021, 139, 111623.
[http://dx.doi.org/10.1016/j.biopha.2021.111623] [PMID: 33915504]
[73]
Loureiro, J.A.; Gomes, B.; Fricker, G.; Coelho, M.A.N.; Rocha, S.; Pereira, M.C. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment. Colloids Surf. B Biointerfaces, 2016, 145, 8-13.
[http://dx.doi.org/10.1016/j.colsurfb.2016.04.041] [PMID: 27131092]
[74]
Ruff, J.; Hüwel, S.; Kogan, M.J.; Simon, U.; Galla, H.J. The effects of gold nanoparticles functionalized with b-amyloid specific peptides on an in vitro model of blood-brain barrier. Nanomedicine, 2017, 13(5), 1645-1652.
[http://dx.doi.org/10.1016/j.nano.2017.02.013] [PMID: 28285163]
[75]
Zhang, J.; Liu, R.; Zhang, D.; Zhang, Z.; Zhu, J.; Xu, L.; Guo, Y. Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer’s disease. Colloids Surf. B Biointerfaces, 2021, 200, 111584.
[http://dx.doi.org/10.1016/j.colsurfb.2021.111584] [PMID: 33508658]
[76]
Xu, L.; Ding, Y.; Ma, F.; Chen, Y.; Chen, G.; Zhu, L.; Long, J.; Ma, R.; Liu, Y.; Liu, J.; Huang, F.; Shi, L. Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer’s Disease. Nano Today, 2022, 43, 101388.
[http://dx.doi.org/10.1016/j.nantod.2022.101388]
[77]
Karimzadeh, M.; Rashidi, L.; Ganji, F. Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev. Ind. Pharm., 2017, 43(4), 628-636.
[http://dx.doi.org/10.1080/03639045.2016.1275668] [PMID: 28043167]
[78]
Ahmad, S.; Hafeez, A. Formulation and development of curcumin–piperine-loaded s-snedds for the treatment of Alzheimer’s disease. Mol. Neurobiol., 2023, 60(2), 1067-1082.
[http://dx.doi.org/10.1007/s12035-022-03089-7] [PMID: 36414909]
[79]
Tak, K.; Sharma, R.; Dave, V.; Jain, S.; Sharma, S. Clitoria ternatea mediated synthesis of graphene quantum dots for the treatment of Alzheimer’s disease. ACS Chem. Neurosci., 2020, 11(22), 3741-3748.
[http://dx.doi.org/10.1021/acschemneuro.0c00273] [PMID: 33119989]
[80]
Li, H.; Luo, Y.; Derreumaux, P.; Wei, G. Carbon nanotube inhibits the formation of β-sheet-rich oligomers of the Alzheimer’s amyloid-β(16-22) peptide. Biophys. J., 2011, 101(9), 2267-2276.
[http://dx.doi.org/10.1016/j.bpj.2011.09.046] [PMID: 22067167]
[81]
Moan, J.; Peng, Q. An outline of the hundred-year history of PDT. Anticancer Res., 2003, 23(5A), 3591-3600.
[PMID: 14666654]
[82]
Lipson, R.L.; Baldes, E.J.; Olsen, A.M. Hematoporphyrin derivative: A new aid for endoscopic detection of malignant disease. J. Thorac. Cardiovasc. Surg., 1961, 42(5), 623-629.
[http://dx.doi.org/10.1016/S0022-5223(19)32560-7] [PMID: 14465760]
[83]
Kessel, D. Photodynamic therapy: From the beginning. Photodiagn. Photodyn. Ther., 2004, 1(1), 3-7.
[http://dx.doi.org/10.1016/S1572-1000(04)00003-1] [PMID: 25048058]
[84]
Dougherty, T.J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg., 2002, 20(1), 3-7.
[http://dx.doi.org/10.1089/104454702753474931] [PMID: 11902352]
[85]
U.S. Food and Drug Administration (FDA) Photofrin (porfimer sodium) Injection, 1995. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020451s020lbl.pdf
[86]
Li, S.; Zhou, S.; Li, Y.; Li, X.; Zhu, J.; Fan, L.; Yang, S. Exceptionally high payload of the 1R780 iodide on folic acid-functionalized graphene quantum dots for targeted photothermal therapy. ACS Appl. Mater. Interfaces, 2017, 9(27), 22332-22341.
[http://dx.doi.org/10.1021/acsami.7b07267] [PMID: 28643511]
[87]
Ren, H.; Liu, J.; Li, Y.; Wang, H.; Ge, S.; Yuan, A.; Hu, Y.; Wu, J. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater., 2017, 59, 269-282.
[http://dx.doi.org/10.1016/j.actbio.2017.06.035] [PMID: 28663143]
[88]
Silindir-Gunay, M.; Sarcan, E.T.; Ozer, A.Y. Near‐infrared imaging of diseases: A nanocarrier approach. Drug Dev. Res., 2019, 80(5), 521-534.
[http://dx.doi.org/10.1002/ddr.21532] [PMID: 30893508]
[89]
Silindir Gunay, M.; Onaral, F.; Kart, D. Design of IR780 ethosomes for imaging and photodynamic/photothermal therapy of infections. Acta Pol. Pharm. Drug Res., 2022, 79, 255-266.
[90]
Silindir Günay, M. The Formulation of methylene blue encapsulated, tc-99m labeled multifunctional liposomes for sentinel lymph node ımaging and therapy. Turk. J. Pharm. Sci., 2020, 17(4), 381-387.
[http://dx.doi.org/10.4274/tjps.galenos.2019.86619] [PMID: 32939133]
[91]
Sarcan, E.T.; Silindir-Gunay, M.; Ozer, A.Y. Theranostic polymeric nanoparticles for NIR imaging and photodynamic therapy. Int. J. Pharm., 2018, 551(1-2), 329-338.
[http://dx.doi.org/10.1016/j.ijpharm.2018.09.019] [PMID: 30244148]
[92]
Wan, M.T.; Lin, J.Y. Current evidence and applications of photodynamic therapy in dermatology. Clin. Cosmet. Investig. Dermatol., 2014, 7, 145-163.
[PMID: 24899818]
[93]
Li, C.; Wang, J.; Liu, L. Alzheimer’s therapeutic strategy: Photoactive platforms for suppressing the aggregation of amyloid β protein. Front Chem., 2020, 8, 509.
[http://dx.doi.org/10.3389/fchem.2020.00509] [PMID: 32793545]
[94]
Wei, G.; Yang, G.; Wang, Y.; Jiang, H.; Fu, Y.; Yue, G.; Ju, R. Phototherapy-based combination strategies for bacterial infection treatment. Theranostics, 2020, 10(26), 12241-12262.
[http://dx.doi.org/10.7150/thno.52729] [PMID: 33204340]
[95]
Huo, J.; Jia, Q.; Huang, H.; Zhang, J.; Li, P.; Dong, X.; Huang, W. Emerging photothermal-derived multimodal synergistic therapy in combating bacterial infections. Chem. Soc. Rev., 2021, 50(15), 8762-8789.
[http://dx.doi.org/10.1039/D1CS00074H] [PMID: 34159993]
[96]
Cheng, L.; He, W.; Gong, H.; Wang, C.; Chen, Q.; Cheng, Z.; Liu, Z. PEGylated micelle nanoparticles encapsulating a non-fluorescent near-ınfrared organic dye as a safe and highly-effective photothermal agent for in vivo cancer therapy. Adv. Funct. Mater., 2013, 23(47), 5893-5902.
[http://dx.doi.org/10.1002/adfm.201301045]
[97]
Wang, K.; Zhang, Y.; Wang, J.; Yuan, A.; Sun, M.; Wu, J.; Hu, Y. Self-assembled IR780-loaded transferrin nanoparticles as an imaging, targeting and PDT/PTT agent for cancer therapy. Sci. Rep., 2016, 6(1), 27421.
[http://dx.doi.org/10.1038/srep27421] [PMID: 27263444]
[98]
Zhen, X.; Xie, C.; Jiang, Y.; Ai, X.; Xing, B.; Pu, K. Semiconducting photothermal nanoagonist for remote-controlled specific cancer therapy. Nano Lett., 2018, 18(2), 1498-1505.
[http://dx.doi.org/10.1021/acs.nanolett.7b05292] [PMID: 29342359]
[99]
Nowak-Stepniowska, A.; Pergoł, P.; Padzik-Graczyk, A. Photodynamic method of cancer diagnosis and therapy-mechanisms and applications. Postepy Biochem., 2013, 59(1), 53-63.
[PMID: 23821943]
[100]
Fonseca, S.M.; Pina, J.; Arnaut, L.G.; Seixas de Melo, J.; Burrows, H.D.; Chattopadhyay, N.; Alcácer, L.; Charas, A.; Morgado, J.; Monkman, A.P.; Asawapirom, U.; Scherf, U.; Edge, R.; Navaratnam, S. Triplet-state and singlet oxygen formation in fluorene-based alternating copolymers. J. Phys. Chem. B, 2006, 110(16), 8278-8283.
[http://dx.doi.org/10.1021/jp060251f] [PMID: 16623508]
[101]
Kwiatkowski, S.; Knap, B.; Przystupski, D.; Saczko, J.; Kędzierska, E.; Knap-Czop, K.; Kotlińska, J.; Michel, O.; Kotowski, K.; Kulbacka, J. Photodynamic therapy – mechanisms, photosensitizers and combinations. Biomed. Pharmacother., 2018, 106, 1098-1107.
[http://dx.doi.org/10.1016/j.biopha.2018.07.049] [PMID: 30119176]
[102]
Robertson, C.A.; Evans, D.H.; Abrahamse, H. Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B, 2009, 96(1), 1-8.
[http://dx.doi.org/10.1016/j.jphotobiol.2009.04.001] [PMID: 19406659]
[103]
Ghosh, M. Recent developments of porphyrin photosensitizers in photodynamic therapy. ChemRxiv, 2023.
[104]
Liu, W.; Dong, X.; Liu, Y.; Sun, Y. Photoresponsive materials for intensified modulation of Alzheimer’s amyloid-β protein aggregation: A review. Acta Biomater., 2021, 123, 93-109.
[http://dx.doi.org/10.1016/j.actbio.2021.01.018] [PMID: 33465508]
[105]
Lee, J.S.; Lee, B.I.; Park, C.B. Photo-induced inhibition of Alzheimer’s β-amyloid aggregation in vitro by rose bengal. Biomaterials, 2015, 38, 43-49.
[http://dx.doi.org/10.1016/j.biomaterials.2014.10.058] [PMID: 25457982]
[106]
Dubey, T.; Gorantla, N.V.; Chandrashekara, K.T.; Chinnathambi, S. Photodynamic exposure of Rose-Bengal inhibits Tau aggregation and modulates cytoskeletal network in neuronal cells. Sci. Rep., 2020, 10(1), 12380.
[http://dx.doi.org/10.1038/s41598-020-69403-2] [PMID: 32704015]
[107]
Uddin, M.M.N.; Bekmukhametova, A.; Antony, A.; Barman, S.K.; Houang, J.; Wu, M.J.; Hook, J.M.; George, L.; Wuhrer, R.; Mawad, D.; Ta, D.; Ruprai, H.; Lauto, A. Encapsulated rose bengal enhances the photodynamic treatment of triple-negative breast cancer cells. Molecules, 2024, 29(2), 546.
[http://dx.doi.org/10.3390/molecules29020546] [PMID: 38276623]
[108]
Shirata, C.; Kaneko, J.; Inagaki, Y.; Kokudo, T.; Sato, M.; Kiritani, S.; Akamatsu, N.; Arita, J.; Sakamoto, Y.; Hasegawa, K.; Kokudo, N. Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress. Sci. Rep., 2017, 7(1), 13958.
[http://dx.doi.org/10.1038/s41598-017-14401-0] [PMID: 29066756]
[109]
Jao, Y.; Ding, S.J.; Chen, C.C. Antimicrobial photodynamic therapy for the treatment of oral infections: A systematic review. J. Dent. Sci., 2023, 18(4), 1453-1466.
[http://dx.doi.org/10.1016/j.jds.2023.07.002] [PMID: 37799910]
[110]
Najm, M.; Pourhajibagher, M.; Badirzadeh, A.; Razmjou, E.; Alipour, M.; Khoshmirsafa, M.; Bahador, A.; Hadighi, R. Photodynamic therapy using toluidine blue o (tbo) dye as a photosensitizer against leishmania major. Iran. J. Public Health, 2021, 50(10), 2111-2120.
[http://dx.doi.org/10.18502/ijph.v50i10.7514] [PMID: 35223579]
[111]
Lee, B.I.; Suh, Y.S.; Chung, Y.J.; Yu, K.; Park, C.B. Shedding light on Alzheimer’s β-amyloidosis: Photosensitized methylene blue ınhibits self-assembly of β-amyloid peptides and disintegrates their aggregates. Sci. Rep., 2017, 7(1), 7523.
[http://dx.doi.org/10.1038/s41598-017-07581-2] [PMID: 28790398]
[112]
Morais, F.A.P.; Campanholi, K.; Balbinot, R.; Junior, R.; Goncalves, R.; de Oliveira, A.C. Characterization of acridine orange in homogeneous media: A supportive study and validation of ıts potential for photo-applications. Arch. Pharm. Pharmacol. Res., 2021, 3(1), 1-5.
[http://dx.doi.org/10.33552/APPR.2021.03.000555]
[113]
Yoo, J-O.; Ha, K-S. Chapter four - New insights into the mechanisms for photodynamic therapy-ınduced cancer cell death. In: International Review of Cell and Molecular Biology; Jeon, K.W., Ed.; Academic Press, 2012; Vol. 295, pp. 139-174.
[http://dx.doi.org/10.1016/B978-0-12-394306-4.00010-1]
[114]
Hak, A.; Ali, M.S.; Sankaranarayanan, S.A.; Shinde, V.R.; Rengan, A.K. Chlorin e6: A promising photosensitizer in photo-based cancer nanomedicine. ACS Appl. Bio Mater., 2023, 6(2), 349-364.
[http://dx.doi.org/10.1021/acsabm.2c00891] [PMID: 36700563]
[115]
Morison, W.; Richard, E. PUVA photochemotherapy and other phototherapy modalities. In: Comprehensive Dermatologic Drug Therapy; Elsevier, 2013.
[http://dx.doi.org/10.1016/B978-1-4377-2003-7.00022-4]
[116]
Lee, Y.; Hyun, C.G. Anti-inflammatory effects of psoralen derivatives on raw264.7 cells via regulation of the NF-κB and MAPK signaling pathways. Int. J. Mol. Sci., 2022, 23(10), 5813.
[http://dx.doi.org/10.3390/ijms23105813]
[117]
Damrongrungruang, T.; Kitchindaopat, N.; Thanasothon, P.; Theeranut, K.; Tippayawat, P.; Ruangsuwan, C.; Suwannee, B. Effects of photodynamic therapy with azulene on peripheral blood mononuclear cell viability and singlet oxygen formation. Photodiagn. Photodyn. Ther., 2018, 24, 318-323.
[http://dx.doi.org/10.1016/j.pdpdt.2018.10.015] [PMID: 30381257]
[118]
Wang, L.; Yan, J.; Fu, P.P.; Parekh, K.A.; Yu, H. Photomutagenicity of cosmetic ingredient chemicals azulene and guaiazulene. Mutat. Res., 2003, 530(1-2), 19-26.
[http://dx.doi.org/10.1016/S0027-5107(03)00131-3] [PMID: 14563527]
[119]
Peng, C.; Li, Y.; Liang, H.; Cheng, J.; Li, Q.; Sun, X.; Li, Z.; Wang, F.; Guo, Y.; Tian, Z.; Yang, L.; Tian, Y.; Zhang, Z.; Cao, W. Detection and photodynamic therapy of inflamed atherosclerotic plaques in the carotid artery of rabbits. J. Photochem. Photobiol. B, 2011, 102(1), 26-31.
[http://dx.doi.org/10.1016/j.jphotobiol.2010.09.001] [PMID: 20875747]
[120]
Hirabayashi, A.; Shindo, Y.; Oka, K.; Takahashi, D.; Toshima, K. Photodegradation of amyloid β and reduction of its cytotoxicity to PC12 cells using porphyrin derivatives. Chem. Commun., 2014, 50(67), 9543-9546.
[http://dx.doi.org/10.1039/C4CC03791J] [PMID: 25012260]
[121]
Lee, B.I.; Chung, Y.J.; Park, C.B. Photosensitizing materials and platforms for light-triggered modulation of Alzheimer’s β-amyloid self-assembly. Biomaterials, 2019, 190-191, 121-132.
[http://dx.doi.org/10.1016/j.biomaterials.2018.10.043] [PMID: 30447644]
[122]
Mangione, M.R.; Palumbo Piccionello, A.; Marino, C.; Ortore, M.G.; Picone, P.; Vilasi, S.; Di Carlo, M.; Buscemi, S.; Bulone, D.; San Biagio, P.L. Photo-inhibition of Aβ fibrillation mediated by a newly designed fluorinated oxadiazole. RSC Advances, 2015, 5(21), 16540-16548.
[http://dx.doi.org/10.1039/C4RA13556C]
[123]
Paban, V; Manrique, C; Filali, M; Maunoir-Regimbal, S; Fauvelle, F; Alescio-Lautier, B Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model. Neuropharmacology, 2014, 76(Pt A), 68-79.
[http://dx.doi.org/10.1016/j.neuropharm.2013.06.033]
[124]
Sontag, E.M.; Lotz, G.P.; Agrawal, N.; Tran, A.; Aron, R.; Yang, G.; Necula, M.; Lau, A.; Finkbeiner, S.; Glabe, C.; Marsh, J.L.; Muchowski, P.J.; Thompson, L.M. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington’s disease models. J. Neurosci., 2012, 32(32), 11109-11119.
[http://dx.doi.org/10.1523/JNEUROSCI.0895-12.2012] [PMID: 22875942]
[125]
Necula, M.; Breydo, L.; Milton, S.; Kayed, R.; van der Veer, W.E.; Tone, P.; Glabe, C.G. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry, 2007, 46(30), 8850-8860.
[http://dx.doi.org/10.1021/bi700411k] [PMID: 17595112]
[126]
Lublin, A.L.; Gandy, S. Amyloid-beta oligomers: Possible roles as key neurotoxins in Alzheimer’s disease. Mt. Sinai J. Med., 2010, 77(1), 43-49.
[http://dx.doi.org/10.1002/msj.20160] [PMID: 20101723]
[127]
Cappai, R.; Barnham, K.J. Delineating the mechanism of Alzheimer’s disease A beta peptide neurotoxicity. Neurochem. Res., 2008, 33(3), 526-532.
[http://dx.doi.org/10.1007/s11064-007-9469-8] [PMID: 17762917]
[128]
Simakova, O.; Arispe, N.J. The cell-selective neurotoxicity of the Alzheimer’s Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J. Neurosci., 2007, 27(50), 13719-13729.
[http://dx.doi.org/10.1523/JNEUROSCI.3006-07.2007] [PMID: 18077683]
[129]
Mitkevich, V.A.; Petrushanko, I.Y.; Yegorov, Y.E.; Simonenko, O.V.; Vishnyakova, K.S.; Kulikova, A.A.; Tsvetkov, P.O.; Makarov, A.A.; Kozin, S.A. Isomerization of Asp7 leads to increased toxic effect of amyloid-β42 on human neuronal cells. Cell Death Dis., 2013, 4(11), e939.
[http://dx.doi.org/10.1038/cddis.2013.492] [PMID: 24287700]
[130]
Ni, C.L.; Shi, H.P.; Yu, H.M.; Chang, Y.C.; Chen, Y.R. Folding stability of amyloid‐β 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J., 2011, 25(4), 1390-1401.
[http://dx.doi.org/10.1096/fj.10-175539] [PMID: 21209058]
[131]
Lee, B.I.; Suh, Y.S.; Chung, Y.J.; Yu, K.; Park, C.B. Shedding light on Alzheimer’s β-amyloidosis: Photosensitized methylene blue inhibits self-assembly of β-amyloid peptides and disintegrates their aggregates. Sci. Rep., 2017, 7(1), 7523.
[http://dx.doi.org/10.1038/s41598-017-07581-2] [PMID: 28790398]
[132]
Wischik, CM; Bentham, P; Wischik, DJ; Seng, KM KM O3-04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's Dement., 2008, 4(4S_Part_5), T167.
[133]
Zhang, J.; Liu, J.; Zhu, Y.; Xu, Z.; Xu, J.; Wang, T.; Yu, H.; Zhang, W. Photodynamic micelles for amyloid β degradation and aggregation inhibition. Chem. Commun., 2016, 52(81), 12044-12047.
[http://dx.doi.org/10.1039/C6CC06175C] [PMID: 27711295]
[134]
Chung, Y.J.; Kim, K.; Lee, B.I.; Park, C.B. Carbon nanodot-sensitized modulation of Alzheimer’s β-amyloid self-assembly, disassembly, and toxicity. Small, 2017, 13(34), 1700983.
[http://dx.doi.org/10.1002/smll.201700983] [PMID: 28714246]
[135]
Du, Z.; Gao, N.; Wang, X.; Ren, J.; Qu, X. Near-infrared switchable fullerene-based synergy therapy for Alzheimer’s disease. Small, 2018, 14(33), 1801852.
[http://dx.doi.org/10.1002/smll.201801852] [PMID: 30028575]
[136]
Zhang, Z.; Han, Q.; Lau, J.W.; Xing, B. Lanthanide-doped upconversion nanoparticles meet the needs for cutting-edge bioapplications: Recent progress and perspectives. ACS Mater. Lett., 2020, 2(11), 1516-1531.
[http://dx.doi.org/10.1021/acsmaterialslett.0c00377] [PMID: 33644762]
[137]
Yu, D.; Guan, Y.; Bai, F.; Du, Z.; Gao, N.; Ren, J.; Qu, X. Metal–Organic frameworks harness cu chelating and photooxidation against amyloid β aggregation in vivo. Chemistry, 2019, 25(14), 3489-3495.
[http://dx.doi.org/10.1002/chem.201805835] [PMID: 30601592]
[138]
Ma, Z.; Song, C.; Yang, K.; Wang, J. PEG-modified copper cysteine for photodynamic therapy in Alzheimer’s disease; Res. Sq, 2022.
[http://dx.doi.org/10.21203/rs.3.rs-1446266/v1]
[139]
Ozawa, S.; Hori, Y.; Shimizu, Y.; Taniguchi, A.; Suzuki, T.; Wang, W.; Chiu, Y.W.; Koike, R.; Yokoshima, S.; Fukuyama, T.; Takatori, S.; Sohma, Y.; Kanai, M.; Tomita, T. Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer’s disease mice. Brain, 2021, 144(6), 1884-1897.
[http://dx.doi.org/10.1093/brain/awab058] [PMID: 33851209]
[140]
Son, G.; Lee, B.I.; Chung, Y.J.; Park, C.B. Light-triggered dissociation of self-assembled β-amyloid aggregates into small, nontoxic fragments by ruthenium (II) complex. Acta Biomater., 2018, 67, 147-155.
[http://dx.doi.org/10.1016/j.actbio.2017.11.048] [PMID: 29221856]
[141]
Ni, J.; Taniguchi, A.; Ozawa, S.; Hori, Y.; Kuninobu, Y.; Saito, T.; Saido, T.C.; Tomita, T.; Sohma, Y.; Kanai, M. Near-infrared photoactivatable oxygenation catalysts of amyloid peptide. Chem, 2018, 4(4), 807-820.
[http://dx.doi.org/10.1016/j.chempr.2018.02.008]
[142]
Zhan, Q.; Shi, X.; Wang, T.; Hu, J.; Zhou, J.; Zhou, L.; Wei, S. Design and synthesis of thymine modified phthalocyanine for Aβ protofibrils photodegradation and Aβ peptide aggregation inhibition. Talanta, 2019, 191, 27-38.
[http://dx.doi.org/10.1016/j.talanta.2018.08.037] [PMID: 30262061]
[143]
Nagashima, N.; Ozawa, S.; Furuta, M.; Oi, M.; Hori, Y.; Tomita, T.; Sohma, Y.; Kanai, M. Catalytic photooxygenation degrades brain Aβ in vivo. Sci. Adv., 2021, 7(13), eabc9750.
[http://dx.doi.org/10.1126/sciadv.abc9750] [PMID: 33762329]
[144]
Leshem, G.; Richman, M.; Lisniansky, E.; Antman-Passig, M.; Habashi, M.; Gräslund, A.; Wärmländer, S.K.T.S.; Rahimipour, S. Photoactive chlorin e6 is a multifunctional modulator of amyloid-β aggregation and toxicity via specific interactions with its histidine residues. Chem. Sci., 2019, 10(1), 208-217.
[http://dx.doi.org/10.1039/C8SC01992D] [PMID: 30713632]
[145]
Ruff, J.; Hassan, N.; Morales-Zavala, F.; Steitz, J.; Araya, E.; Kogan, M.J.; Simon, U. CLPFFD–PEG functionalized NIR-absorbing hollow gold nanospheres and gold nanorods inhibit β-amyloid aggregation. J. Mater. Chem. B Mater. Biol. Med., 2018, 6(16), 2432-2443.
[http://dx.doi.org/10.1039/C8TB00655E] [PMID: 32254460]
[146]
Ma, M.; Wang, Y.; Gao, N.; Liu, X.; Sun, Y.; Ren, J.; Qu, X. A near-İnfrared-controllable artificial metalloprotease used for degrading amyloid-β monomers and aggregates. Chemistry, 2019, 25(51), 11852-11858.
[http://dx.doi.org/10.1002/chem.201902828] [PMID: 31361361]
[147]
Sudhakar, S.; Mani, E. Rapid dissolution of amyloid β fibrils by silver nanoplates. Langmuir, 2019, 35(21), 6962-6970.
[http://dx.doi.org/10.1021/acs.langmuir.9b00080] [PMID: 31030521]
[148]
Liu, Z.; Ma, M.; Yu, D.; Ren, J.; Qu, X. Target-driven supramolecular self-assembly for selective amyloid-β photooxygenation against Alzheimer’s disease. Chem. Sci., 2020, 11(40), 11003-11008.
[http://dx.doi.org/10.1039/D0SC04984K] [PMID: 34094349]
[149]
Liu, Y.; Chen, Y.; Gong, Y.; Yang, H.; Liu, J. Polydopamine/Ruthenium nanoparticle systems as photothermal therapy reagents and reactive oxygen species scavengers for Alzheimer’s disease treatment. ACS Appl. Nano Mater., 2023, 6(7), 5384-5393.
[http://dx.doi.org/10.1021/acsanm.2c05512]
[150]
Idée, J.M.; Louguet, S.; Ballet, S.; Corot, C. Theranostics and contrast-agents for medical imaging: A pharmaceutical company viewpoint. Quant. Imaging Med. Surg., 2013, 3(6), 292-297.
[PMID: 24404442]
[151]
Jeelani, S.; Jagat Reddy, R.C.; Maheswaran, T.; Asokan, G.S.; Dany, A.; Anand, B. Theranostics: A treasured tailor for tomorrow. J. Pharm. Bioallied Sci., 2014, 6(5)(Suppl. 1), 6.
[http://dx.doi.org/10.4103/0975-7406.137249] [PMID: 25210387]
[152]
Hilderbrand, S.A.; Weissleder, R. Near-infrared fluorescence: Application to in vivo molecular imaging. Curr. Opin. Chem. Biol., 2010, 14(1), 71-79.
[http://dx.doi.org/10.1016/j.cbpa.2009.09.029] [PMID: 19879798]
[153]
Silindir, M.; Erdoğan, S.; Özer, A.Y.; Maia, S. Liposomes and their applications in molecular imaging. J. Drug Target., 2012, 20(5), 401-415.
[http://dx.doi.org/10.3109/1061186X.2012.685477] [PMID: 22553977]
[154]
Silindir, M.; Özer, A.Y.; Erdoğan, S. The use and importance of liposomes in positron emission tomography. Drug Deliv., 2012, 19(1), 68-80.
[http://dx.doi.org/10.3109/10717544.2011.635721] [PMID: 22211758]
[155]
Blasberg, R.G. Molecular imaging and cancer. Mol. Cancer Ther., 2003, 2(3), 335-343.
[PMID: 12657729]
[156]
Massoud, T.F.; Gambhir, S.S. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev., 2003, 17(5), 545-580.
[http://dx.doi.org/10.1101/gad.1047403] [PMID: 12629038]
[157]
GB, S. Instruments for radiation detection and measurements. In: Fundamentals of Nuclear Pharmacy; Springer: New York, 2004.
[158]
Silindir Gunay, M.; Yekta Ozer, A.; Chalon, S. Drug delivery systems for ımaging and therapy of Parkinson’s disease. Curr. Neuropharmacol., 2016, 14(4), 376-391.
[http://dx.doi.org/10.2174/1570159X14666151230124904] [PMID: 26714584]
[159]
Li, M.; Guan, Y.; Zhao, A.; Ren, J.; Qu, X. Using multifunctional peptide conjugated au nanorods for monitoring β-amyloid aggregation and chemo-photothermal treatment of Alzheimer’s disease. Theranostics, 2017, 7(12), 2996-3006.
[http://dx.doi.org/10.7150/thno.18459] [PMID: 28839459]
[160]
Liu, D.; Li, W.; Jiang, X.; Bai, S.; Liu, J.; Liu, X.; Shi, Y.; Kuai, Z.; Kong, W.; Gao, R.; Shan, Y. Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer’s disease. Theranostics, 2019, 9(8), 2268-2281.
[http://dx.doi.org/10.7150/thno.30649] [PMID: 31149043]
[161]
Gong, L.; Zhang, X.; Ge, K.; Yin, Y.; Machuki, J.O.; Yang, Y.; Shi, H.; Geng, D.; Gao, F. Carbon nitride-based nanocaptor: An intelligent nanosystem with metal ions chelating effect for enhanced magnetic targeting phototherapy of Alzheimer’s disease. Biomaterials, 2021, 267, 120483.
[http://dx.doi.org/10.1016/j.biomaterials.2020.120483] [PMID: 33129186]
[162]
Sharma, M.; Tiwari, V.; Chaturvedi, S.; Wahajuddin, M.; Shukla, S.; Panda, J.J. Self-Fluorescent lone tryptophan nanoparticles as theranostic agents against Alzheimer’s disease. ACS Appl. Mater. Interfaces, 2022, 14(11), 13079-13093.
[http://dx.doi.org/10.1021/acsami.2c01090] [PMID: 35263093]

Rights & Permissions Print Cite